BBLG
Bone Biologics Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.
Market Cap: 1.25 Million
Primary Exchange: NASDAQ
Shares Outstanding: 534 Thousand
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.5908834693695137
Sector: Manufacturing
Industry: Surgical Appliance and Supplies Manufacturing
Ethical Flags
Longest drawdown: 548 trading days
From: 2021-11-01 To: 2023-06-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|